Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Hoa Q. Trummell"'
Autor:
Sindhu Nair, Hoa Q Trummell, Rajani Rajbhandari, Nanda K Thudi, Susan E Nozell, Jason M Warram, Christopher D Willey, Eddy S Yang, William J Placzek, James A Bonner, Markus Bredel
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0229077 (2020)
Epidermal growth factor receptor (EGFR) is a pro-tumorigenic receptor tyrosine kinase that facilitates growth for cancer cells that overexpress the receptor. Monoclonal anti-EGFR antibody Cetuximab (CTX) provides significant clinical benefit in patie
Externí odkaz:
https://doaj.org/article/20ddfc5b974349a48705b8719e140d9b
Autor:
Catherine P. Langford, James A. Mobley, Kadia Cosby, Hoa Q. Trummell, Nicholas Eustace, Anita B. Hjelmeland, James A. Bonner, Patricia H. Hicks, Rune T. Pedersen, James R. Hackney, Joshua C. Anderson, G. Yancey Gillespie, Christopher D. Willey, John S. Jarboe
Publikováno v:
International Journal of Oncology
Glioblastoma harbors frequent alterations in receptor tyrosine kinases, phosphatidylinositol-3 kinase (PI3K) and phosphatase and tensin homolog (PTEN) that dysregulate phospholipid signaling driven tumor proliferation and therapeutic resistance. Myri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d42171e4b10d10961843274780ff389
http://europepmc.org/articles/PMC6521926
http://europepmc.org/articles/PMC6521926
Autor:
Christopher D. Willey, Hoa Q. Trummell, Jason M. Warram, Rajani Rajbhandari, Nanda K. Thudi, Sindhu Nair, Susan Nozell, Markus Bredel, William J. Placzek, James A. Bonner, Eddy S. Yang
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0229077 (2020)
PLoS ONE
PLoS ONE
Epidermal growth factor receptor (EGFR) is a pro-tumorigenic receptor tyrosine kinase that facilitates growth for cancer cells that overexpress the receptor. Monoclonal anti-EGFR antibody Cetuximab (CTX) provides significant clinical benefit in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb5f9744540971f510952d8a2fe9589a
https://doaj.org/article/20ddfc5b974349a48705b8719e140d9b
https://doaj.org/article/20ddfc5b974349a48705b8719e140d9b
Autor:
Kaitlyn A. Dorsett, Hoa Q. Trummell, Donald J. Buchsbaum, Eddy S. Yang, Patsy G. Oliver, Asmi Chakraborty, Susan L. Bellis, James A. Bonner
Publikováno v:
Journal of Biological Chemistry. 293:984-994
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Gemcitabine, as a single agent or in combination therapy, remains the frontline chemotherapy despite its limited efficacy due to de novo or acquired chemoresis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54e02f4042bf783d39139219823bc1a
https://doi.org/10.1074/jbc.m117.808584
https://doi.org/10.1074/jbc.m117.808584
Autor:
Christopher D. Willey, Rik de Wijn, Eddy S. Yang, Markus Bredel, Joshua C. Anderson, Hoa Q. Trummell, Faris Naji, James A. Bonner, Nanda K. Thudi
Publikováno v:
Biochemical and biophysical research communications. 517(1)
Acquired cetuximab resistance is a challenge for oncologists treating advanced head and neck carcinoma (HNC). While intrinsic cetuximab resistance mechanism in colorectal cancer is known, resistance in HNC is unclear. We established two different cet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a927c10f135425f26f09bd73d8a285ea
https://pubmed.ncbi.nlm.nih.gov/31311651
https://pubmed.ncbi.nlm.nih.gov/31311651
Publikováno v:
Annals of Oncology. 30:ix105-ix106
Background Cetuximab (an inhibitor of EGFR) is commonly utilized for the treatment of head and neck cancers. It has been employed in combination with radiation or multi-agent chemotherapy for locoregionally advanced and metastatic head and neck cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf9ce949010f42ecb6271a31ed9c698c
https://doi.org/10.1093/annonc/mdz428.028
https://doi.org/10.1093/annonc/mdz428.028
Autor:
Tiffiny S. Cooper, Hoa Q. Trummell, Alice N. Weaver, Eben L. Rosenthal, Marcela Rodriguez, Eddy S. Yang, James A. Bonner
Publikováno v:
Oncotarget
Patients with human papillomavirus-positive (HPV+) head and neck squamous cell carcinomas (HNSCCs) have increased response to radio- and chemotherapy and improved overall survival, possibly due to an impaired DNA damage response. Here, we investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86b2232c459e219d08dd693ca69fa5a7
http://europepmc.org/articles/PMC4694969
http://europepmc.org/articles/PMC4694969
Autor:
Christopher D. Willey, Patricia H. Hicks, John S. Jarboe, Joshua C. Anderson, Timothy D. Rohrbach, Gene P. Siegal, Hoa Q. Trummell, Chad Steele, Eddy S. Yang, Alice N. Weaver, Jessy S. Deshane, James A. Bonner, Robert A. Oster
Publikováno v:
International Journal of Oncology. 46:1079-1088
Lung cancer is the leading cause of cancer related deaths. Common molecular drivers of lung cancer are mutations in receptor tyrosine kinases (RTKs) leading to activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pro-growth, pro-survival signal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a188e6e048e08cea14a8c6668c085c8d
https://doi.org/10.3892/ijo.2014.2799
https://doi.org/10.3892/ijo.2014.2799
Autor:
James A. Bonner, Hoa Q. Trummell
Publikováno v:
Annals of Oncology. 29:ix148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fec9d741299cad6717c17062c2aa0ab2
https://doi.org/10.1093/annonc/mdy446.013
https://doi.org/10.1093/annonc/mdy446.013
Publikováno v:
Radiotherapy and Oncology. 92:339-344
Background Signal transducer and activator of transcription-3 (STAT-3) is a downstream component of the Epidermal Growth Factor Receptor (EGFr) signaling process that may facilitate the resistance of tumor cells to conventional cancer treatments. Stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b4ca19233c4fc3f76e03dd8263acd8
https://doi.org/10.1016/j.radonc.2009.06.022
https://doi.org/10.1016/j.radonc.2009.06.022